Research and Clinical Trials on Zolpidem (Ambien, Stilnoct)

avatar image
By Dr Greg Mulhauser

This list of current clinical research trials on Zolpidem (Ambien, Stilnoct) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Zolpidem (Ambien, Stilnoct) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Zolpidem (Ambien, Stilnoct).

 

Get These Clinical Trials as a Newsfeed

Zolpidem:     Get the Zolpidem clinical trials feed.    Add the Zolpidem clinical trials feed to your My Yahoo! page.    Add the Zolpidem clinical trials feed to your MyMSN page.

Current Research Literature on Zolpidem (Ambien, Stilnoct)

Here are abstracts for some of the latest research articles to have appeared on Zolpidem (Ambien, Stilnoct):

Zolpidem-induced sleep-related eating disorder.

J Neurol Sci. 2009 Oct 10;
Yun CH, Ji KH
An association between zolpidem administration and sleep-related eating disorder (SRED) has been suggested. The authors observed zolpidem-induced SRED in restless legs syndrome (RLS). With the review of previous reports, we identified a common occurrence of RLS in zolpidem-induced SRED.

Zolpidem dependence in a geriatric patient: a case report.

J Am Geriatr Soc. 2009 Oct; 57(10): 1962-3
Spyridi S, Diakogiannis I, Nimatoudis J, Iacovides A, Kaprinis G

Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study.

Psychopharmacology (Berl). 2009 Oct 2;
Meskali M, Berthelon C, Marie S, Denise P, Bocca ML
RATIONALE: The effects of hypnotic drugs on driving performance are most often evaluated on young healthy subjects by using a monotonous motorway driving test. The effects of drugs in urban driving situations have not yet been evaluated in any age group. Our objectives were to assess residual effects of the most prescribed hypnotics, zolpidem and zopiclone, on older middle-age drivers' capacities in an urban situation. MATERIALS AND METHODS: Sixteen healthy subjects aged 55 to 65 years underwent this double-blind, balanced, cross-over study. Zopiclone (7.5 mg), zolpidem (10 mg), and flunitrazepam (1 mg; used as positive control) or a placebo were administered at each subject's home at 11:00 PM: under the supervision of an investigator. The next morning, the subjects had to drive in a simulated urban environment where accident scenarios were introduced. Accident scenarios were implemented using data from real accident cases. RESULTS: Hypnotics did not significantly increase the number of collisions. However, significantly higher speeds were found with zopiclone and flunitrazepam; moreover, zolpidem and zopiclone induced modifications of the lateral position of the car on the road. CONCLUSIONS: This study did not reveal any major residual effects of the hypnotics studied on driving performance in aging drivers. However, the urban driving situations used here for the first time in the evaluation of drugs revealed some modifications in driving habits which could lead to risky behavior. It thus appears that urban driving simulations are useful for gaining knowledge about the effects of drugs on driving behavior.

Short half-life hypnotics preserve physical fitness and altitude tolerance during military mountainous training.

Mil Med. 2009 Sep; 174(9): 964-70
Jouanin JC, Dussault C, Van Beers P, Piérard C, Beaumont M
OBJECTIVE: We study the effect of short half-life hypnotics (zaleplon or zolpidem against placebo) on altitude tolerance in 12 nonacclimated male soldiers (age, 22.1 +/- 0.8 years; height, 177.8 +/- 1.7 cm; weight, 69.8 +/- 1.7 kg). METHODS: Soldiers were trained to practice mountaineering at high altitude (2,533-4,810 meters) during 3 periods (one per medication tested) of 4 days (D1-D4). In each period the nights were spent in a hut (3,613 m). Administration of hypnotics or placebo was then implemented at 9:45 p.m. Nocturnal arterial oxygen saturation (SaO2) and heart rate variability (HRV) were monitored. At 5:00 a.m. and 9:00 p.m. physical fitness was assessed using acute mountain sickness (AMS) score. At 5:00 p.m., a posteffort stand test was carried out to evaluate the orthoparasympathetic imbalance with fatigue. RESULTS: Nocturnal SaO2 correlated negatively with morning AMS scores (R = -0.820, p < 0.02) and HRV analysis favored the sympathetic modulation. Posteffort stand tests revealed that sympathetic modulation attenuated from D2 to D3 in treated groups. CONCLUSION: The present study provides evidence that zolpidem or zaleplon improves sleep and subsequent physical fitness at altitude.

[Zolpidem dependance and withdrawal seizure]

Rev Med Liege. 2009 Jul-Aug; 64(7-8): 407-8
Pitchot W, Ansseau M
Zolpidem is an imidazopiridine with hypnotic properties. Compared to benzodiazepines, zolpidem has a mechanism of action that is thought to reduce the risk of dependence or abuse. However, in the past 10 years, several cases of zolpidem abuse, dependence and withdrawal reactions have been described in the litterature. Here, we describe a case of dependence and withdrawal seizure.

 

This page was last reviewed by Dr Greg Mulhauser, Monday, 1 June 2009.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/zolpidem-research.html